Article Information
History
- May 18, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Vivek Shinde, MD, MPH1,*,
- Rongman Cai, PhD2,
- Joyce Plested, PhD1,
- Iksung Cho, MS1,
- Jamie Fiske, MS1,
- Xuan Pham, PhD2,
- Mingzhu Zhu, PhD1,
- Shane Cloney-Clark, BS1,
- Nan Wang, MS2,
- Haixia Zhou, PhD1,
- Bin Zhou, PhD1,
- Nita Patel, MS1,
- Michael J Massare, PhD1,
- Amy Fix, MS, MBA2,
- Michelle Spindler, MS2,
- David Nigel Thomas, PhD2,
- Gale Smith, PhD1,
- Louis Fries, MD1 and
- Gregory M Glenn, MD1,†
- 1Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA
- 2Previously with Novavax, Inc., 20 Firstfield Road, Gaithersburg, MD, USA
- ↵*Corresponding Author: Vivek Shinde (vshinde{at}novavax.com). Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA 20878, Tel: 1-240-238-0842
- ↵†Contact information for Alternate Corresponding Author: Greg Glenn (gglenn{at}novavax.com), Novavax, Inc., 22 Firstfield Road, Gaithersburg, MD, USA 20878, Tel: 1-240-268-2019
Posted May 18, 2020.
Induction of Cross-reactive Hemagglutination Inhibiting Antibody and Polyfunctional CD4+ T-cell Responses by a Recombinant Matrix-M-Adjuvanted Hemagglutinin Nanoparticle Influenza Vaccine
